The EMA recently launched a public consultation on their “Draft proposal for an addendum, on transparency, to the “Functional specifications for the EU portal and EU database to be audited – EMA/42176/2014”, for proposals and options on the application of exceptions in relation to the transparency provisions of the European Clinical Trial Regulation.
Following the review of the EMA’s proposals, the AHPPI have submitted a joint response to the consultation together with all associations incorporated into the European Federation for Exploratory Medicines Development (EUFEMED).
Click here to download the response
AHPPI committee members actively participate in the ongoing discussions and stakeholder meetings on a European and UK level. Any additional feedback and support from our members is most welcome.